drugset / Trial / NCT02209779

Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis

NCT02209779

Phase 2 Completed 167 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective was to determine the effects of BIRB 796 BS on CRP and clinical parameters in Rheumatoid Arthritis as measures of efficacy, and on population pharmacokinetics and safety parameters

Timeline

Start
2001-05
Primary completion
2002-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBR 796 BS Unknown 5 mg Oral
Subject BIBR 796 BS Unknown 10 mg Oral
Subject BIBR 796 BS Unknown 20 mg Oral
Subject BIBR 796 BS Unknown 30 mg Oral

Indications